Faecal calprotectin and lactoferrin values during irradiation of prostate cancer correlate with chronic radiation proctitis: Results of a prospective study

References

• Hille A, Schmidberger H, Hermann RM, Christiansen H, Saile B, Pradier O, et al. A phase III randomized, placebo controlled, double-blind study of misoprostol rectal suppositories in the prevention of acute radiation proctitis in patients with prostate cancer. Int J Radiat Oncol Biol Phys 2005; 63: 1488–93
   PubMed Web of Science ®Google Scholar
• Koper PC, Stroom JC, van Putten WL, Korevaar GA, Heijmen BJ, Wijnmaalen A, et al. Acute morbidity reduction using 3D-CRT for prostate carcinoma: a randomized study. Int J Radiat Oncol Biol Phys 1997; 43: 727–34
   Web of Science ®Google Scholar
• Michalski JM, Purdy JA, Winter K, Roach M III, Vijayakumar S, Sandler HM, et al. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys 2000; 46: 391–402
   PubMed Web of Science ®Google Scholar
• O'Brien PC, Franklin CI, Dear KB, Hamilton CC, Poulsen M, Joseph DJ, et al. A phase III double-blind randomised study of rectal sucralfate suspension in the prevention of acute radiation proctitis. Radiother Oncol 1997; 45: 117–23
   PubMed Web of Science ®Google Scholar
• Schultheiss TE, Lee WR, Hunt MA, Hanlon AL, Peter RS, Hanks GE. Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 1997; 37: 3–11
   PubMed Web of Science ®Google Scholar
• Weiss E, Hirnle P, Arnold-Bofinger H, Hess CF, Bamberg M. Therapeutic outcome and relation of acute and late side effects in the adjuvant radiotherapy of endometrial carcinoma stage I and II. Radiother Oncol 1999; 53: 37–44
   PubMed Web of Science ®Google Scholar
• Babb RR. Radiation proctitis: a review. Am J Gastroenterol 1996; 91: 1309–11
   PubMed Web of Science ®Google Scholar
• Miller AR, Martenson JA, Nelson H, Schleck CD, Ilstrup DM, Gunderson LL, et al. The incidence and clinical consequences of treatment-related bowel injury. Int J Radiat Oncol Biol Phys 1999; 43: 817–25
   PubMed Web of Science ®Google Scholar
• Pilepich MV, Krall J, George FW, Asbell SO, Plenk HD, Johnson RJ, et al. Treatment-related morbidity in phase III RTOG studies of extended-field irradiation for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1984; 10: 1861–7
   PubMed Web of Science ®Google Scholar
• Smit WG, Helle PA, van Putten WL, Wijnmaalen AJ, Seldenrath JJ, van der Werf-Messing BH. Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose. Int J Radiat Oncol Biol Phys 1990; 18: 23–9
   PubMed Web of Science ®Google Scholar
• Richter KK, Wang J, Fagerhol MK, Hauer-Jensen M. Radiation-induced granulocyte transmigration predicts development of delayed structural changes in rat intestine. Radiother Oncol 2001; 59: 81–5
   PubMed Web of Science ®Google Scholar
• Dai J, Liu WZ, Zhao YP, Hu YB, Ge ZZ. Relationship between fecal lactoferrin and inflammatory bowel disease. Scand J Gastroenterol 2007; 42: 1440–4
   PubMed Web of Science ®Google Scholar
• Gisbert JP, González-Lama Y, Maté J. Role of biological markers in inflammatory bowel disease. Gastroenterol Hepatol 2007; 30: 117–29
   PubMedGoogle Scholar
• Gisbert, JP, McNicholl, AG, Gomollon, F. Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. Inflamm Bowel Dis 2009. Epub ahead of print.
   Web of Science ®Google Scholar
• Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008; 103: 162–9
   PubMed Web of Science ®Google Scholar
• Ho GT, Lee HM, Brydon G, Ting T, Hare N, Drummond H, et al. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol 2009; 104: 673–8
   PubMed Web of Science ®Google Scholar
• Røseth AG, Kristinsson J, Fagerhol MK, Schjønsby H, Aadland E, Nygaard K, et al. Faecal calprotectin: a novel test for the diagnosis of colorectalcancer?. Scand J Gastroenterol 1993; 28: 1073–6
   PubMed Web of Science ®Google Scholar
• Larsen A, Hovdenak N, Karlsdottir A, Wentzel-Larsen T, Dahl O, Fagerhol MK. Faecal calprotectin and lactoferrin as markers of acute radiation proctitis: a pilot study of eight stool markers. Scand J Gastroenterol 2004; 39: 1113–8
   PubMed Web of Science ®Google Scholar
• Larsen A, Bjørge B, Klementsen B, Helgeland L, Wentzel-Larsen T, Fagerhol MK, et al. Time patterns of changes in biomarkers, symptoms and histopathology during pelvic radiotherapy. Acta Oncol 2007; 46: 639–50
   PubMed Web of Science ®Google Scholar
• Hille A, Schmidt-Giese E, Hermann RM, Herrmann MK, Rave-Fränk M, Schirmer M, et al. A prospective study of faecal calprotectin and lactoferrin in the monitoring of acute radiation proctitis in prostate cancer treatment. Scand J Gastroenterol 2008; 43: 52–8
   PubMed Web of Science ®Google Scholar
• Wedlake L, McGough C, Hackett C, Thomas K, Blake P, Harrington K, et al. Can biological markers act as non-invasive, sensitive indicators of radiation-induced effects in the gastrointestinal mucosa?. Aliment Pharmacol Ther 2008; 27: 980–7
   PubMed Web of Science ®Google Scholar
• Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, et al. Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000; 47: 13–47
   PubMed Web of Science ®Google Scholar
• LENT soma scales for all anatomic sites. Int J Radiat Oncol Biol Phys 1995;31:1049–91.
   PubMedGoogle Scholar
• International Commission on Radiation Units and Measurements. ICRU Report 50: Prescribing, recording, and reporting photon beam therapy. Washington, DC: International Commission on Radiation Units and Measurements; 1993.
   Google Scholar
• Hovdenak N, Fajardo LF, Hauer-Jensen M. Acute radiation proctitis: a sequential clinicopathologic study during pelvic radiotherapy. Int J Radiat Oncol Biol Phys 2000; 48: 1111–7
   PubMed Web of Science ®Google Scholar
• Sedgwick DM, Howard GC, Ferguson A. Pathogenesis of acute radiation injury to the rectum. A prospective study in patients. Int J Colorectal Dis 1994; 9: 23–30
   PubMed Web of Science ®Google Scholar
• Gul YA, Prasannan S, Jabar FM, Shaker AR, Moissinac K. Pharmacotherapy for chronic hemorrhagic radiation proctitis. World J Surg 2002; 26: 1499–502
   PubMed Web of Science ®Google Scholar
• Donner CS. Pathophysiology and therapy of chronic radiation-induced injury to the colon. Dig Dis 1998; 16: 253–61
   PubMed Web of Science ®Google Scholar
• Haboubi NY, Schofield PF, Rowland PL. The light and electron microscopic features of early and late phase radiation-induced proctitis. Am J Gastroenterol 1988; 83: 1140–4
   PubMed Web of Science ®Google Scholar
• Hasleton PS, Carr N, Schofield PF. Vascular changes in radiation bowel disease. Histopathology 1985; 9: 517–34
   PubMed Web of Science ®Google Scholar
• Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 2004; 39: 1017–20
   PubMed Web of Science ®Google Scholar
• Sugi, K O. , Saitoh, I . Hirata, I , Katsu, K. Fecal lactoferrin as a marker for disease activity in inflammatory bowel: comparison with other neutrophil derived proteins. Am J Gastroenterol 1996;91:927–34.
   PubMed Web of Science ®Google Scholar
• Levay PF, Viljoen M. Lactoferrin: a general review. Haematologica 1995; 80: 252–67
   PubMed Web of Science ®Google Scholar
• Voganatsi A, Panyutich A, Miyasaki KT, Murthy RK. Mechanism of extracellular release of human neutrophil calprotectin complex. J Leukoc Biol 2001; 70: 130–4
   PubMed Web of Science ®Google Scholar
• Rammes A, Roth J, Goebeler M, Klempt M, Hartmann M, Sorg C. Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway. J Biol Chem 1997; 272: 9496–502
   PubMed Web of Science ®Google Scholar
• Kayazawa M, Saitoh O, Kojima K, Nakagawa K, Tanaka S, Tabata K, et al. Lactoferrin in whole gut lavage fluid as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol 2002; 97: 360–9
   PubMed Web of Science ®Google Scholar
• Silberer H, Küppers B, Mickisch O, Baniewicz W, Drescher M, Traber L, et al. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome. Clin Lab 2005; 51: 117–26
   PubMed Web of Science ®Google Scholar
• Denham JW, O'Brien PC, Dunstan RH, Johansen J, See A, Hamilton CS, et al. Is there more than one late radiation proctitis syndrome?. Radiother Oncol 1999; 51: 43–53
   PubMed Web of Science ®Google Scholar